Canaccord analyst Mark Massaro raised his price target on Genomic Health to $82 from $70 following its beat and raise Q3 results. The analyst cited its topline growth and raised top and bottom line outlook for the year. Massaro reiterated his Buy rating on Genomic Health shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.